Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients

Cardiovasc Ther. 2020 Mar 10:2020:3568608. doi: 10.1155/2020/3568608. eCollection 2020.

Abstract

Children with Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG) have a higher incidence of coronary artery lesions (CAL). Despite the association between Purinergic receptor P2Y12 (P2RY12) polymorphism, KD genetic susceptibility, and CAL complications being proved, few studies have assessed the relationship between P2RY12 polymorphisms and IVIG resistance in patients with KD. We recruited 148 KD patients with IVIG resistance and 611 with IVIG sensitivity and selected five P2RY12 polymorphisms: rs9859538, rs1491974, rs7637803, rs6809699, and rs2046934. A significant difference in the genotype distributions between patients was only observed for the rs6809699 A > C polymorphism (AC vs. AA: adjusted odds ratio (OR) = 0.48, 95% confidence interval (CI) = 0.27-0.84, P=0.011; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27-0.83, P=0.0084). After adjusting for age and gender, the carriers of the rs6809699 C allele had OR of 0.44 to 0.49 for IVIG sensitivity (AC vs. AA: adjusted OR = 0.48, 95% confidence interval (CI) = 0.27-0.84, P=0.011; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27-0.83, P=0.0084) compared to the carriers of a rs6809699 AA genotype, suggesting the protective effect of this SNP against IVIG resistance. Moreover, individuals with all five protective polymorphisms experienced a significantly decreased IVIG resistance compared to that of individuals with up to three protective polymorphisms (adjusted OR = 0.27, 95% CI = 0.13-0.57, P=0.0006). Our results suggest that the P2RY12 rs6809699 polymorphism could be used as a biomarker to predict IVIG resistance in KD patients.

MeSH terms

  • Adolescent
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Clinical Decision-Making
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / genetics*
  • Coronary Artery Disease / immunology
  • Coronary Artery Disease / prevention & control*
  • Drug Resistance / genetics*
  • Female
  • Gene Frequency
  • Heterozygote
  • Homozygote
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Infant
  • Male
  • Mucocutaneous Lymph Node Syndrome / diagnosis
  • Mucocutaneous Lymph Node Syndrome / drug therapy*
  • Mucocutaneous Lymph Node Syndrome / genetics*
  • Mucocutaneous Lymph Node Syndrome / immunology
  • Patient Selection
  • Pharmacogenomic Testing
  • Pharmacogenomic Variants*
  • Polymorphism, Single Nucleotide*
  • Predictive Value of Tests
  • Receptors, Purinergic P2Y12 / genetics*
  • Risk Factors

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • P2RY12 protein, human
  • Receptors, Purinergic P2Y12